{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-26-000162","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2026-07-30T10:53:18+00:00","discovered_at":"2026-07-30T10:55:00.508282+00:00","generated_at":"2026-07-30T10:55:06.557382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Labcorp Q2 revenue up 5.8% to $3.73B, adjusted EPS $4.99 beats; raises FY guidance","bullets":["Q2 diluted EPS $3.64 vs $2.84 (+28.5%); adjusted EPS $4.99 vs $4.35 (+14.9%), beating prior guidance.","Revenue $3.73B, up 5.8% YoY; Diagnostics Labs +5.5%, Biopharma +6.5%.","Raised FY 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint); revenue growth 5.4%-6.3%.","Board approved $1.0B increase in share repurchase authorization, total remaining $1.4B.","Completed acquisitions of Parkview Health outreach services and Tribal Diagnostics; quarterly dividend $0.72."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-26-000162","json":"https://secwatch.observer/filing/0000920148-26-000162.json","markdown":"https://secwatch.observer/filing/0000920148-26-000162.md","text":"https://secwatch.observer/filing/0000920148-26-000162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/0000920148-26-000162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/lh-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T10:55:06.557382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}